|
grantnews.
|
AMANET awards three grants to
African institutions |
AMANET is pleased
to announce awarding of capacity strengthening and site
development grants as well as clinical trials grants for 2005.
This follows the call for applications which was sent out in
March 2004 and a rigorous selection process.
During the fifth meeting of the AMANET Board of Trustees, held
on 25 November 2004 in Dar es Salaam, Tanzania, grants were
awarded to CNRFP, TDRC Ndola, NIMR Amani. €200,000 was awarded
to CNRFP Burkina Faso, a centre that remains as a shining
example of the achievements of AMANET capacity strengthening
grants. The grant is for site maintenance that will enable the
centre to continue with its capacity strengthening programme
in preparation for further vaccine trials.
Tropical Disease Research Center (TDRC) Ndola in Zambia and
National Institute for Medical Research (NIMR), Amani,
Tanzania have each been granted €250,000. These grants are for
institutional capacity strengthening including site
characterization and will last for two years.
AMANET is also pleased to announce the plans to undertake a
phase 1b trial of the Apical Membrane Antigen (AMA 1). This
follows successful application from the developer through the
European Malaria Vaccine Initiative (EMVI). The selected trial
site is the Malaria Research and Training Centre (MRTC),
University of Bamako, Mali. The phase 1b trial is expected to
start in October 2005.
Other planned trials for the 2005 include GMZ-2, a hybrid
molecule of recombinant Merozoite Surface Protein (MSP3) and
Glutamate Rich Protein (GLURP) Further development of MSP3
vaccine will depend on the outcome of the phase 1b trial which
has just been completed under AMANET funding at CNRFP, Burkina
Faso. |
|
|
|
|
The African Malaria Network Trust
[AMANET]
Tanzania Commission for Science and Technology Building
P.O. Box 33207,Dar es Salaam, Tanzania
Tel: 255 (022) 2700018, Fax: 255 (022) 2700380
General Email:
info@amanet-trust.org
|
|
|
|
